Penwest Pharmaceuticals — Investor Presentation (December 2008)
17 slides from Penwest Pharmaceuticals's investor presentation, Dec 4, 2008
Slide 1: Corporate Presentation December 2008
Corporate Presentation December 2008
Slide 2: Forward-looking Statements
Forward-looking Statements The matters discussed herein contain forward-looking statements that involve risks and uncertainties, which may cause the actual results in future periods to be materially different from any future performance suggested herein. For this purpose, any statements contained he
Slide 3: 2009 Strategy for Penwest
Balance short term economic pressures with long term goal of growing shareholder value The Company's plan for 2009 consists of the following key components: Manage the Company to ensure there is no need to raise additional capital. Manage the Company to be profitable in 2010 and possibly profitable
Slide 4: 2009 Value Drivers
2009 Value Drivers We believe that by pursuing this strategy we can enter into 2010: As a profitable and cash flow positive Company. Continuing to protect shareholders from additional dilution. Leveraging currently unvalued assets to create long term growth. With a potentially "meaningful" compound
Slide 5: 2008 Accomplishments
2008 Accomplishments Opana ER Increased scripts and market share Began receiving royalties Penwest leading efforts to outlicense Opana ex-US A0001 Completed IND enabling tox studies Filed IND and held Pre-IND meeting Completed single ascending dose safety study Made progress on selection of second N
Slide 6: Opana ER: Sales Update and Patents
Sales Update Patents Opana(r) ER
Slide 7: Opana ER Weekly TRx Physician Demand Nearly Doubled During 2008
7 WAC/tab Opana ER Weekly TRx Physician Demand Nearly Doubled During 2008 Source: IMS Weekly Data TRx volume is now nearly 10,000 per week Demand has nearly doubled over the course of 2008 Market share based on weekly data has risen along with total volume
Slide 8: Prosecution Status of Endo Patent Applications
Prosecution Status of Endo Patent Applications Serial Number Expiration if issued Claims Status 10/190,192 July 3, 2022 A method of controlling pain Endo expects to file Appeal Brief by year end. 3 PK Patents (not published) 2022-2027 PK & label claims Filed under expedited review. Endo expects to f
Slide 9: A0001 Lead Compound
A0001 A0001 Lead Compound Co-enzyme Q class of drug. High dose co-enzyme Q supplementation is thought to have an effect in mitochondrial diseases. A0001 is more bioavailable than co-enzyme Q. Marketed in the 70's in France as a compound for hypertension and various myopathies. Small molecule designe
Slide 10: A0001 Opportunity
A0001 Opportunity Growing scientific understanding of the role mitochondria plays in various diseases and increasing interest in the space by pharma. Significant unmet medical need for mitochondrial respiratory chain disorders. Orphan drug exclusivity (7 years) for mitochondrial respiratory chain di
Slide 11: A0001 2008 Development
A0001 2008 Development Completed IND enabling tox studies for A0001 in Q1 ^08 Met with FDA H1 ^08 and Filed IND Completed Phase I single dose safety studies for A0001
Slide 12: A0001 2009 Next Steps
A0001 2009 Next Steps Complete multiple ascending dose safety study H1 '09 Complete clinical trial proof of concept data in mitochondrial patients Initiate 6 month tox program
Slide 13: Recent Financial Results
Recent Financial Results ($ in thousands) 2007 Q1 '08 Q2 '08 Q3 '08 Revenues $ 3,308 $ 739 $ 1,316 $ 1,361 Gross Profit 2,703 570 808 1,039 SG&A 14,260 4,324 3,071 2,247 R&D (Excl. Named Prog. Spend) 12,733 3,044 2,447 2,709 R&D Named Program Spend 10,828 3,341 2,077 3,179 Total R&D Expense 23,561 6
Slide 14: Projected 2009 Cash Spend vs. 2008 Estimate
Projected 2009 Cash Spend vs. 2008 Estimate 2009 2008 Debt Service Debt Service $ 6.0m $3.6m Programs Programs 4.0m 12m -13m Salary, Benefits & Other Comp Salary, Benefits & Other Comp 54-58% Other Major Items (in order of size): Other Major Items (in order of size): Other Major Items (in order of s
Slide 15: Key Financial Points
Key Financial Points We expect year end 2008 cash to be above the previous guidance of $14-16 million. Our 2009 business plan is designed to avoid being forced to finance. We plan to maintain a cash balance of $10+ million at all times during 2009. We expect to be profitable for the full year 2010 a
Slide 16: 2009 Key Events
2009 Key Events Opana ER Increasing sales Clarity around IP Financial Strength Profitability in 2010 and possibly Q4 '09 Manage cash to ensure no need to finance Leverage unvalued assets Outlicensing deals being pursued for Opana ex-US, nalbuphine, drug delivery A0001 Complete multiple ascending dos
Slide 17: Penwest
AaFenwest
Penwest Pharmaceuticals — Investor Presentation (December 2008) on 6ix